Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Upgraded to “Strong Sell” by Barclays

Barclays upgraded shares of Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) to a strong sell rating in a research note issued to investors on Tuesday, Zacks.com reports.

Separately, Royal Bank of Canada raised Recordati Industria Chimica e Farmaceutica to a “hold” rating in a report on Monday, October 7th.

Recordati Industria Chimica e Farmaceutica Stock Performance

OTCMKTS:RCDTF opened at $52.25 on Tuesday. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.36 and a quick ratio of 0.95. Recordati Industria Chimica e Farmaceutica has a 1 year low of $52.25 and a 1 year high of $52.25. The business has a fifty day moving average of $52.25 and a 200-day moving average of $51.87.

Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) last announced its earnings results on Tuesday, July 30th. The company reported $0.70 earnings per share (EPS) for the quarter. The firm had revenue of $622.00 million during the quarter. Recordati Industria Chimica e Farmaceutica had a net margin of 17.41% and a return on equity of 30.78%.

Recordati Industria Chimica e Farmaceutica Company Profile

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.